ADMA Biologics (NASDAQ:ADMA – Get Free Report) is one of 842 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare ADMA Biologics to similar companies based on the strength of its institutional ownership, dividends, profitability, analyst recommendations, risk, earnings and valuation.
Risk & Volatility
ADMA Biologics has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500. Comparatively, ADMA Biologics’ rivals have a beta of -1.85, suggesting that their average stock price is 285% less volatile than the S&P 500.
Valuation & Earnings
This table compares ADMA Biologics and its rivals top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| ADMA Biologics | $510.17 million | $146.93 million | 17.10 |
| ADMA Biologics Competitors | $688.58 million | $7.69 million | -17.98 |
ADMA Biologics’ rivals have higher revenue, but lower earnings than ADMA Biologics. ADMA Biologics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Insider & Institutional Ownership
75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 3.9% of ADMA Biologics shares are owned by insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares ADMA Biologics and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ADMA Biologics | 35.14% | 42.56% | 26.96% |
| ADMA Biologics Competitors | -12,224.75% | -204.85% | -31.52% |
Analyst Ratings
This is a summary of current recommendations for ADMA Biologics and its rivals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ADMA Biologics | 0 | 3 | 3 | 0 | 2.50 |
| ADMA Biologics Competitors | 9926 | 15343 | 45765 | 1601 | 2.54 |
ADMA Biologics presently has a consensus target price of $17.50, suggesting a potential upside of 32.88%. As a group, “Biotechnology” companies have a potential upside of 114.76%. Given ADMA Biologics’ rivals stronger consensus rating and higher probable upside, analysts clearly believe ADMA Biologics has less favorable growth aspects than its rivals.
Summary
ADMA Biologics beats its rivals on 7 of the 13 factors compared.
About ADMA Biologics
ADMA Biologics is a biopharmaceutical company that develops, manufactures and markets plasma-derived therapies for people with immune deficiencies and certain infectious diseases. Its products include BIVIGAM and ASCENIV, intravenous immune globulin therapies used to treat primary humoral immunodeficiency, and Nabi-HB, an immune globulin used for hepatitis B prevention in specific clinical settings. The company collects human plasma through its U.S. donor centers and processes it into therapies at its manufacturing facility in Boca Raton, Florida.
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
